Mallinckrodt is no stranger to legal challenges, having fought payer lawsuits over extravagant Acthar price hikes and federal subpoenas for its sale of powerful opioids. Facing claims an acquired company paid off doctors for scripts, the drugmaker will square off against the feds once again.
